None listed
Conditions
Brief summary
This study aims to better understand how obesity and type 2 diabetes affect the heart before symptoms or disease are clinically diagnosed. We will use advanced MRI scans and blood tests to measure heart structure, function, energy use, fat content, and blood vessel health. Participants will include healthy adults and those with obesity or type 2 diabetes. The results will help researchers identify early warning signs of heart disease and improve how we prevent or treat it in the future. All participants will attend one research visit at the Baker Heart and Diabetes Institute in Melbourne.
Interventions
Comprehensive cardiovascular magnetic resonance imaging and multi-omic profiling for cardiometabolic health assessment.
Detailed description of exposure:
Participants will undergo a single comprehensive study visit (optionally split into two shorter visits at participant preference) conducted at the Baker Heart and Diabetes Institute, Melbourne. The intervention includes:
Cardiovascular magnetic resonance (CMR) imaging:
Structural, functional, and perfusion imaging of the heart, with pharmacol
Comprehensive cardiovascular magnetic resonance imaging and multi-omic profiling for cardiometabolic health assessment. Detailed description of exposure: Participants will undergo a single comprehensive study visit (optionally split into two shorter visits at participant preference) conducted at the Baker Heart and Diabetes Institute, Melbourne. The intervention includes: Cardiovascular magnetic resonance (CMR) imaging: Structural, functional, and perfusion imaging of the heart, with pharmacological stress agent (adenosine), and administration of gadolinium-based contrast. This will take approximately 60 minutes. Magnetic resonance spectroscopy (MRS): Proton (¹H-MRS) spectroscopy to assess myocardial lipid content. Phosphorus (³¹P-MRS) spectroscopy to evaluate myocardial energetics (phosphocreatine-to-ATP ratio). This will take around 30 minutes. Functional exercise testing: Six-minute walk test to assess functional capacity. This will take around 15 minutes. Blood sampling and multi-omic profiling: Approximately 20 mL of fasting blood collected to profile proteomic, lipidomic, and metabolomic biomarkers. This will take roughly 10 minutes. Samples processed immediately and stored securely at -80°C for subsequent analysis. Quality-of-life assessment: Participants will complete the validated EQ-5D-5L questionnaire. This will take approximately 10 minutes to complete. Clinical Data Recording: Collection of demographic, anthropometric, and clinical information. This will take roughly 5 minutes. Duration and Frequency: Single research visit (approximately 3-4 hours total, or split visits if preferred by participant). Clinical outcomes may be monitored via routine health care records for up to 3 years. All imaging and physiological assessments are non-invasive, apart from standard venepuncture and intravenous contrast administration. The visit is conducted under clinical supervision by trained research staff and medical personnel.
Sponsors
Baker Heart & Diabetes Institute - Cardiometabolic Imaging Lab
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
• Male or female over 18 years of age; • Adults with established diagnosis of T2D according to WHO criteria • Adults with overweight/obesity (BMI greater than or equal to 25kg/m2who are suitable to undergo CMR scans, e.g. less than 120kg) • Normal body weight healthy control participants (BMI less than or equal to 25) with no current or prior diagnosis or treatment for any current or past diagnosis of disease, are asymptomatic and are not on regular prescription medication (contraceptives and occasional analgesia permitted). • Eligible for Medicare.
Exclusion criteria
• Contra-indications to MRI (including any concern about metallic foreign bodies); • Pregnancy or breastfeeding • Known hypersensitivity to adenosine (ever requiring hospital admission with asthma or chronic obstructive pulmonary disease) or gadolinium. • History of ischaemic heart disease, cardiomyopathy. • More than mild valvular dysfunction. • Established diagnosis of heart failure preserved or reduced ejection fraction. • Significant renal impairment (eGFR less than 30mL/min/1.73m2).
Outcome results
None listed